George Clinical Scientific Leader research contributions recognized with leading Lancet profile.

George Clinical Scientific Leader research contributions recognized with leading Lancet profile.

George Clinical welcomes the recognition of Professor Craig Anderson as profiled in the premier medical journal The Lancet which identified him as “a front runner in stroke research”. “It is our engagement with scientific leaders, such as Professor Anderson, that sets George Clinical apart from other CROs,” said Philip Gregory, Managing Director, China. “The Lancet […]

Read More

January 29th, 2019
Research confirms link between birthweight and cancer

Research confirms link between birthweight and cancer

New research from the International Childhood Cancer Cohort Consortium (I4C) confirms that childhood cancer is linked to birthweight. The incidence of childhood cancer appears to be slowly rising, at a rate of approximately 1% per year in developed countries. Link between birthweight and cancer Risk rose by 26 percent for every kilogram increase in birthweight for […]

Read More

December 17th, 2016
Part II Insights on CT environment – Sth Korea

Part II: Insights on the Clinical Trial Landscape of South Korea

Japan has taken significant steps in establishing itself as a major player in the global clinical research community, driving the demand for more clinical trials across East Asia as a result. By officially acknowledging and seeking clinical data from the Asia-Pacific region, Japan is facilitating a dialogue with one of the most powerful and capable […]

Read More

December 5th, 2016
Part I Clinical trial environment in China

Part I – The clinical trial landscape of the Asia-Pacific, Japan

On the heels of our recent post on our presence at this week’s DIA Japan 2015, BBK welcomes Philip Gregory, the General Manager of George Clinical – CRO China as our guest contributor. With more than 20 years of experience in pharmaceutical, biotech and medical device marketing, Mr. Gregory has spent over 14 years supporting the […]

Read More

December 3rd, 2016
Overcoming the diversity in the South East Asian region

Overcoming the diversity in the South East Asian region for a global clinical trial

Sponsors are increasingly seeking emerging areas to conduct clinical trials for new patient pools and better recruitment. However, successful implementation of these trials in areas such as South East Asia requires operational strategies that circumvents the inherent diversity of these regions. In these regions, language, culture, infrastructure and resources are very different from country to […]

Read More

December 3rd, 2016
Overcoming recruitment challenges in a type 2 diabetes study

Overcoming recruitment challenges in a type 2 diabetes study

Patient recruitment is crucial for the success of any clinical trial. The main objective of recruiting is to identify suitable patients that meet protocol requirements, allowing protocol questions to be answered. However, patient recruitment does not always go to plan. The leading cause of missed clinical trial deadlines is patient recruitment, taking up a significant […]

Read More

December 1st, 2016

The Scientific Leadership Model an Innovative Approach to Clinical Trial Leadership, Design and Delivery

In this webinar, featured speakers, Professor Craig Anderson and Emma Field define and discuss the emergence of the Scientific Leadership Model as an innovative service addition to a clinical trials design and delivery in Asia. This presentation will also showcase the results and success of one of the largest obstructive sleep apnea medical device trials […]

Read More

November 30th, 2016
New Data shows SGLT2 inhibitors may be effective in preventing Kidney Failure

New Data shows SGLT2 Inhibitors May be effective in preventing Kidney Failure

New data presented at the American Society of Nephrology meeting in San Diego last November offers new hope to people with diabetes at risk of kidney disease and kidney failure. They suggest a new class of glucose-lowering agents, sodium glucose co-transporter type 2 (SGLT2) inhibitors, may be effective in preventing kidney failure. This data has […]

Read More

November 27th, 2016
Lowering blood pressure to decrease risk of cardiovascular events

Lowering blood pressure to decrease risk of cardiovascular events

Globally, there are millions of people that could benefit from an intensive lowering of blood pressure (BP). An individual with lower BP decreases their chances of suffering from any cardiovascular events such as: stroke, heart disease or heart attacks. A new study shows that lowering blood pressure to less than 140 mm Hg, the current […]

Read More

November 21st, 2016

Add George Clinical to your network